WuXi Biologics

Last updated
WuXi Biologics
Company type Public
SEHK:  2269
Hang Seng Index Component
ISIN KYG970081173
Industry
Founded2015;9 years ago (2015) in Wu Xi City, China
HeadquartersPrimary: 108 Meiliang Road, Mashan, Binhu District, Wuxi, Jiangsu, China, 214092
Area served
Worldwide
Key people
Subsidiaries WuXi Vaccines
CMAB Biopharma Group
Website www.wuxibiologics.com OOjs UI icon edit-ltr-progressive.svg
Footnotes /references
[1] [2] [3] [4]

WuXi Biologics is a global Contract Research Development and Manufacturing Organization (CRDMO) that provides open-access, integrated technology platforms for biologics drug development.

Contents

WuXi Biologics' roots date back to 2010, and began building out capabilities and facilities required for biologics discovery, development and GMP manufacturing. [5] WuXi Biologics went public on the Hong Kong Stock Exchange in June 2017. [6]

As of 2021, WuXi Biologics has 18 manufacturing sites including ten in China, three in the United States, two in Ireland, two in Germany, and one in Singapore. [7]

In August 2020, WuXi Biologics was selected to become a component of the Hang Seng Index in Hong Kong. [8]

In January 2024, WuXi Biologics' share price fell on news that the United States Congress had introduced legislation to block any federal government contracts with the company due to national security concerns. [9] [10] [11] The concerns stem from allegations, denied by the company, that it has worked closely with the People's Liberation Army as a part of the Chinese Communist Party's military-civil fusion strategy. [12] Members of the United States House Select Committee on Strategic Competition between the United States and the Chinese Communist Party subsequently called for sanctions against WuXi Biologics. [13]

Facilities in Asia

Shanghai, China

WuXi Biologics has two sites in Shanghai, one in the Shanghai Waigaoqiao Free Trade Zone and the other in Fengxian.[ citation needed ]

Wuxi, China

WuXi Biologics has two sites located in Wu Xi City, China. The Mashan site contains MFG1, MFG2, MFG4 and MFG5. [14] and the Wuxi New Area site contains labs dedicated to the antibody drug conjugate development and production. With 30,000 liters of capacity, MFG2 was the world's largest single-use bioreactor production facility which was replaced in that metric by MFG5 which has a 60,000 liter capacity and opened on February 9, 2021. [15] [16]

Hangzhou, China

As of March 2021, WuXi Biologics will have two sites in Hangzhou China.

On March 17, 2021, WuXi Biologics announced an equity agreement with Pfizer China to acquire its newly built $350 million Hangzhou global biotechnology center site and facilities (MFG20). Expected to close in the first half of 2021, the deal includes the 50,000 m2 (540,000 sq ft) of facilities which have been GMP operational since 2018 and are equipped with 2X2000L single-use bioreactors with the ability to expand up to 4X2000L single-use bioreactors. Also included in the acquisition are vial filling (DP9) and pre-filled syringe (DP10) fill and finish lines. [17] Opened in 2020 and slated to be GMP-ready in 2021, the Hangzhou site (MFG13) is home to facilities dedicated to the development and GMP manufacture of recombinant proteins and plasmid DNA produced via microbial fermentation along with separate facilities for the development and production of a viral-based vaccine. [15]

Suzhou, China

As of March 2021, WuXi Biologics will have two sites located in the city of Suzhou, China.

On March 18, 2021, WuXi Biologics announced a purchase agreement with CBC Group which will allow it to acquire over a 90% interest in CMAB Biopharma Group. The transaction is expected to close in the second quarter of 2021. Along with the controlling stake, WuXi Biologics will also acquire a 7000L bioreactor capacity manufacturing facility (MFG21) in Suzhou and associated liquid and lyophilization (DP21) fill and finish production lines. [18] A second site, opened in 2014 is 108,716 sq ft (10,100.0 m2) and was the first non-governmentally affiliated biosafety testing facility in Asia. The facility performs cell line characterization, viral clearance validation studies, and unprocessed bulk lot release. [15]

Chengdu, China

Currently slated to open in 2023, the Chengdu facility (MFG12) will be a 1.3×10^6 sq ft (120×10^3 m2), with an integrated manufacturing center for innovative biologics and dedicated to R&D and commercial-scale bulk API production with an initial bioreactor capacity of 48,000 liters (11,000 imp gal; 13,000 U.S. gal) for commercial production and 5,000 liters (1,100 imp gal; 1,300 U.S. gal) for clinical production. [15] [19]

Shijiazhuang, China

Currently slated to open in 2022, the Shijiazhuang facility MFG8 will be 884,363 sq ft (82,160.0 m2) and dedicated to development and API manufacturing with an initial bioreactor capacity of 48,000 liters. [15]

Singapore

On May 24, 2018, WuXi Biologics announced it will be building a $60 million facility (MFG10) in Singapore which will feature an initial bioreactor capacity of 4,500 liters made up of two 2,000 liter fed-batch reactors and one 500 liter continuous processing perfusion reactor to open in 2023. [15] The project is backed by the Singapore Economic Development Board and will be dedicated to clinical and small volume commercial production as well as early-stage bioprocess development. [20]

Facilities in Europe

Leverkusen, Germany Facility

On January 17, 2020, WuXi Biologics and Bayer announced an acquisition agreement in which WuXi Biologics would take over the operations and lease a 139,931 sq ft (13,000.0 m2) fill site in Leverkusen, Germany. Based on the agreement, the site would perform the final fill-finish of various biologics products produced by WuXi's API sites, and act as a backup for filling operations for Bayer's Kovaltry anti-hemophilic infusions which are primarily finished in another plant in Berkeley, California. [21]

Wuppertal, Germany Facility

On December 21, 2020, WuXi Biologics and Bayer announced a new acquisition agreement for a drug substance (DS) production site for €150 million in Wuppertal, Germany. [22]

Dundalk, Ireland Site

Active ingredient production facilities

In April 2018, [23] WuXi Biologics announced plans to build a new biologics drug substance manufacturing facility on 26 hectares (64 acres) in Dundalk, Ireland. The project is directly supported by the Irish Government through IDA Ireland, with a cost of approximately $394 million. When completed, the facility will be one of the world's largest plants supporting single-use bioreactors and will help accelerate the development of biologic drugs in Europe. [24] MFG6 will have a perfusion bioreactor capacity of 6,000 liters in a continuous bioprocessing configuration and MFG7 will have a 48,000 liter bioreactor capacity in a traditional fed-batch configuration. [25]

Vaccine production facility

In November 2019, WuXi Vaccines, a subsidiary of WuXi Biologics, announced that it would invest an additional $240 million to build a new 167,056 sq ft (15,520.0 m2) vaccine manufacturing facility at the Dundalk, Ireland site. The vaccine site planned includes drug substance manufacturing facilities, drug product manufacturing, Manufacturing Science and Technology Labs as well as Quality Control labs. In February 2020, WuXi Vaccines announced it had signed a 20-year, $3 billion contract with an unidentified "global vaccine leader" to produce one of the unidentified company's vaccine products at the new facility. [26]

Facilities in the United States

Massachusetts

In May 2020, WuXi Biologics announced that it had secured a deal with the Worcester Business Development Corporation at The Reactory, a master-planned manufacturing hub project in Worcester, Massachusetts. The two-story, 107,000 sq ft (9,900 m2) facility will cost $60 million and will employ 150 when it is completed in 2022. The Worcester City Council granted a 20-year, $11.5 million tax increment financing plan to help seal the deal. The new facility will have 16,000 liters of bioreactor capacity, which will include four 4,000-liter traditional fed-batch units and one 500-liter perfusion-based continuous processing unit and will be named MFG11. [27]

New Jersey

In June 2020, WuXi Biologics announced that it had signed a ten-year lease for a 66,000 sq ft (6,100 m2) clinical manufacturing facility (MFG18) in Cranbury, NJ. The facility had previously been leased by Outlook Therapeutics and will install a total of 6,000 liters (1,300 imp gal; 1,600 U.S. gal) of bioreactor capacity, process development, and quality control labs, along with supporting functions. [28]

Pennsylvania

In May 2020, WuXi Biologics announced it had leased a 33,000 sq ft (3,100 m2) process development lab in King of Prussia, Pennsylvania at Discovery Labs, a former GlaxoSmithKline manufacturing site. [29]

Related Research Articles

<span class="mw-page-title-main">TSMC</span> Taiwanese semiconductor foundry company

Taiwan Semiconductor Manufacturing Company Limited is a Taiwanese multinational semiconductor contract manufacturing and design company. It is the world's second most valuable semiconductor company, the world's largest dedicated independent ("pure-play") semiconductor foundry, and its country's largest company, with headquarters and main operations located in the Hsinchu Science Park in Hsinchu, Taiwan. It is majority owned by foreign investors, and the central government of Taiwan is the largest shareholder. In 2023, the company was ranked 44th in the Forbes Global 2000.

FUJIFILM Diosynth Biotechnologies, abbreviated FDB and also referred to simply as Diosynth, is a biopharmaceutical contract manufacturing organization that develops manufacturing processes and manufactures active ingredients and provides fill and finish services for pharmaceutical companies. FUJIFILM Diosynth Biotechnologies is the world's second largest contract manufacturer of biopharmaceuticals, with manufacturing facilities in Morrisville, North Carolina and College Station, Texas in the United States, Teesside, United Kingdom and Hillerød, Denmark in Europe, and recently added sites in Thousand Oaks, California and Watertown, Massachusetts. FUJIFILM Diosynth Biotechnologies operates a highly automated multipurpose manufacturing facility in College Station, Texas under the federal government's Center for Innovation in Advanced Development and Manufacturing (CIADM) program, which is the largest scale-out cell culture manufacturing facility in the United States.

<span class="mw-page-title-main">Las Vegas Convention Center</span> Convention center in Nevada

The Las Vegas Convention Center is a convention center in Winchester, Nevada. It is owned and operated by the Las Vegas Convention and Visitors Authority.

<span class="mw-page-title-main">Hino Motors</span> Japanese commercial vehicle and diesel engine company

Hino Motors, Ltd., commonly known as Hino, is a Japanese manufacturer of commercial vehicles and diesel engines headquartered in Hino, Tokyo. The company was established in 1942 as a corporate spin-off from previous manufacturers.

<span class="mw-page-title-main">Vancouver Convention Centre</span> Convention centre in Vancouver, British Columbia, Canada

The Vancouver Convention Centre is a convention centre in Vancouver, British Columbia, Canada; it is one of Canada's largest convention centres. With the opening of the new West Building in 2009, it now has 43,340 square metres (466,500 sq ft) of meeting space. It is owned by the British Columbia Pavilion Corporation, a Crown corporation owned by the government of British Columbia. The Centre served as the main press centre and International Broadcast Centre for the 2010 Winter Olympics.

<span class="mw-page-title-main">Cambrex Corporation</span> American pharmaceutical company

Cambrex Corporation is a Contract Development Manufacturing Organisation (CDMO) that provides drug substance, drug product and analytical services across the entire drug lifecycle, as well as active pharmaceutical ingredients (APIs). With over 2,200 employees in 7 countries across 13 locations, Cambrex operates in branded and generic markets for API and dosage form development and manufacturing.

<span class="mw-page-title-main">Lonza Group</span> Swiss pharmaceutical and biotech company

Lonza Group is a Swiss multinational manufacturing company for the pharmaceutical, biotechnology and nutrition sectors, headquartered in Basel, with major facilities in Europe, North America and South Asia. Lonza was established under that name in the late 19th-century in Switzerland. The company provides product development services to the pharmaceutical and biologic industries, including custom manufacturing of biopharmaceuticals and detection systems and services for the bioscience sector.

A contract manufacturing organization (CMO), more recently referred to as a contract development and manufacturing organization (CDMO) to avoid the acronym confusion of Chief Medical Officer or Clinical Monitoring Organization in the pharma industry, is a company that serves other companies in the pharmaceutical industry on a contract basis to provide comprehensive services from drug development through drug manufacturing. This allows major pharmaceutical companies to outsource those aspects of the business, which can help with scalability or can allow the major company to focus on drug discovery and drug marketing instead.

WuXi AppTec is a global pharmaceutical, biopharmaceutical, and medical device company.

<span class="mw-page-title-main">JN-International Medical Corporation</span> Pharmaceutical company in Nebraska, United States

JN-International Medical Corporation (JNIMC) is a U.S.-based biopharmaceutical corporation which since 1998 has been focused on developing vaccines and diagnostics for infectious disease for developing countries. This private corporation was founded in 1998 by Dr. Jeeri R. Reddy with the help of Dr. Kelly F. Lechtenberg in a small rural town, Oakland, Nebraska. From there it grew and expanded until in the year 2000 the corporation moved to Omaha, Nebraska.

<span class="mw-page-title-main">Chaudhary Charan Singh International Airport</span> International airport in Lucknow, Uttar Pradesh, India

Chaudhary Charan Singh International Airport is an international airport serving Lucknow, the capital of the Indian state of Uttar Pradesh. It is located in Amausi, 14 km (8.7 mi) from the city centre, and was earlier known as ''Amausi Airport''. It is named after Chaudhary Charan Singh, the fifth Prime Minister of India. It is owned and operated by the Lucknow International Airport Limited (LIAL), a public–private consortium led by Adani Group.

Rubicon Research is an IP led, specialty pharmaceutical company located in Mumbai, India. Its formulation development is across multiple dosage forms, oral solids, oral liquids, nasal, ophthalmic, topical, injectable, fixed dose combinations, and drug device combinations. In 2019 the company received USD 100 million in growth capital investment from General Atlantic, a growth equity firm.

<span class="mw-page-title-main">Biological E. Limited</span> Indian biopharmaceutical company

Biological E Limited is an Indian biotechnology and biopharmaceutical company based in Hyderabad, Telangana. It specialises in the areas of low-cost vaccine production.

NCBioImpact is a group of organizations in the U.S. state of North Carolina created to enhance the trained workforce for biotechnology and other life science employers by educating students and retraining incumbent workers. The partnership works to promote economic development in North Carolina while offering comprehensive biomanufacturing training and education programs located at two universities in the University of North Carolina System and the North Carolina Community College System.

Curia is a contract research and manufacturing organization that provides drug discovery, development, cGMP manufacturing and aseptic fill and finish to the pharmaceutical and biotechnology industries. Founded in 1991, Curia operates in the United States, Europe and Asia, with its headquarters located in Albany, New York. Curia has announced deals and collaborations with such companies as Pfizer Inc., Merck & Co., Eli Lilly and Co., Takeda, Genentech, Bristol-Myers Squibb Co. and GE.

<span class="mw-page-title-main">Samsung Biologics</span> South Korean biotechnology company

Samsung Biologics is a South Korean biotechnology company headquartered in Songdo, Incheon, South Korea. The biotech division of Samsung Group, it provides contract development and manufacturing (CDMO) services to the biopharmaceutical industry.

Ology Bioservices is a private, American biopharmaceutical company headquartered in Alachua, Florida. The company was founded with research in nanometer-scale particle technology to develop new drug delivery technologies and increase the efficacy of existing drugs. In 2016, the company changed their strategic focus and became a biologics contract development and manufacturing company (CDMO) specializing in the manufacturing of vaccines, monoclonal antibodies, recombinant proteins, virus and nucleic acids.

Biotechnology in India is a sunrise sector within the Indian economy. Agencies of the Government of India concerned with the biotechnology industry include the Department of Biotechnology and the proposed Biotechnology Regulatory Authority of India. As of 2022, the sector is valued at $80 billion. Biotechnology in India is in a growth phase and the sector is expected to be valued at $150 billion by 2025 and surpass $300 billion in value by 2030.

Rentschler Biopharma SE is an contract development and manufacturing organization (CDMO). It is part of Dr. Rentschler Holding GmbH & Co. KG and its employees make up the majority of the 1300 workers employed by the parent organization.

References

  1. ↑ "Leadership". WuXi Biologics. Archived from the original on 2020-12-02. Retrieved 2020-12-06.
  2. ↑ "Annual Financial Reports". WuXi Biologics. Archived from the original on 2020-12-02. Retrieved 2020-12-06.
  3. ↑ "WuXi Vaccines Overviewlanguage=en-US". Archived from the original on 2020-12-03. Retrieved 2020-12-06.
  4. ↑ "WuXi Biologics to acquire CMAB Biopharma Grouplanguage=en-US" . Retrieved 2021-03-18.
  5. ↑ "CHNA ETF Video Series: WuXi Biologics". loncarfunds.com. Archived from the original on 2019-08-14. Retrieved 2019-08-14.
  6. ↑ "UPDATE 2-WuXi Biologics prices HK IPO at top as investors seek..." Reuters. 2017-06-06. Archived from the original on 2019-08-14. Retrieved 2019-08-14.
  7. ↑ "Global Network". WuXi Press Release. 2020-12-06. Archived from the original on 2020-12-02. Retrieved 2020-12-06.
  8. ↑ "Alibaba, Xiaomi, WuXi Biologics to join Hang Seng Index". S&P Global Market Intelligence. 2020-12-06. Archived from the original on 2023-01-10. Retrieved 2020-12-06.
  9. ↑ "WuXi Bio Denies Military Ties After Shares Slumped on US Bill". Bloomberg News . 2024-01-29. Archived from the original on 2024-01-29. Retrieved 2024-01-30.
  10. ↑ "WuXi AppTec Shares Continue Slide After Company Calls U.S. Draft Bill Findings Inaccurate" . The Wall Street Journal . January 28, 2024. Archived from the original on January 29, 2024. Retrieved January 29, 2024.
  11. ↑ "WuXi Company Shares Tumble on U.S. Bill Aimed at Chinese Biotech" . The Wall Street Journal . February 2, 2024. Archived from the original on February 1, 2024. Retrieved February 2, 2024.
  12. ↑ Cheung, Sunny; Hope, Arran; Mattis, Peter (February 9, 2024). "Red Genes: Assessing WuXi AppTec's Ties to the Party-Army-State in China". Jamestown Foundation . Archived from the original on 2024-02-10. Retrieved 2024-02-11.
  13. ↑ Martina, Michael (February 12, 2024). "US lawmakers call for sanctions on China's WuXi AppTec biotech firm". Reuters . Retrieved February 12, 2024.
  14. ↑ "Facilities". WuXi Biologics. Archived from the original on 2021-01-10. Retrieved 2020-12-06.
  15. 1 2 3 4 5 6 "Facilities". WuXi Biologics. Archived from the original on 2020-12-02. Retrieved 2020-12-06.
  16. ↑ "The World's Largest 36,000L Biomanufacturing Line Using Single-use Bioreactors Launches GMP Operation at WuXi Biologics" (Press release). PRN. Archived from the original on 2021-02-11. Retrieved 2021-02-15.
  17. ↑ "Facilities" (Press release). WuXi Biologics. Archived from the original on 2021-03-17. Retrieved 2021-03-18.
  18. ↑ "Facilities" (Press release). WuXi Biologics. Archived from the original on 2021-03-18. Retrieved 2021-03-18.
  19. ↑ "WuXi Biologics to build 1.3m-sq-ft manufacturing centre". biopharma-reporter. 16 May 2019. Archived from the original on 2020-10-01. Retrieved 2020-12-06.
  20. ↑ Chapman, Sophie (16 May 2020). "WuXi Biologics to construct $60mn facility in Singapore". Manufacturing Digital Magazine. Archived from the original on 11 August 2022. Retrieved 16 May 2022.
  21. ↑ "WuXi Biologics taking over Bayer plant..." FiercePharma. 2020-01-16. Archived from the original on 2021-01-21. Retrieved 2020-12-06.
  22. ↑ "WuXi Bio lays out €150M to take over Bayer plant in Germany, boosting pandemic supply network". FiercePharma. Archived from the original on 2020-12-22. Retrieved 2020-12-23.
  23. ↑ "WuXi Biologics' Biologics Manufacturing Facility, Dundalk, Ireland". Pharmaceutical Technology. Archived from the original on 2019-08-14. Retrieved 2019-08-14.
  24. ↑ "Jacobs Wins Contract to Provide Construction Services for WuXi". GEN - Genetic Engineering and Biotechnology News. 2019-06-10. Archived from the original on 2019-06-11. Retrieved 2019-08-14.
  25. ↑ "WuXi Biologics Completes Biologics Mfg. Facility in Ireland". Contract Pharma. 2020-03-11. Archived from the original on 2020-09-19. Retrieved 2020-12-06.
  26. ↑ "WuXi Vaccines inks $3B manufacturing deal with 'global vaccine leader'". BioPharmaDive. 2020-02-21. Archived from the original on 2020-11-07. Retrieved 2020-12-06.
  27. ↑ "WuXi Biologics clinches deal to build first U.S. facility at Boston area hub". FiercePharma. 2020-05-19. Archived from the original on 2020-11-03. Retrieved 2020-12-06.
  28. ↑ "WuXi Biologics expands US presence with 6,000L NJ plant". BioProcessIntl. 2020-06-10. Archived from the original on 2020-07-29. Retrieved 2020-12-06.
  29. ↑ "Exclusive: Fast-growing biotech firm takes King of Prussia space, plans 100 new jobs". Philadelphia Business Journal. 2020-05-05. Archived from the original on 2021-05-08. Retrieved 2020-12-23.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.